Muller WA: Diabetes mellitus–long time survival. J Insur Med. 1998, 30: 17-27.
CAS
PubMed
Google Scholar
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414: 813-820. 10.1038/414813a.
Article
CAS
PubMed
Google Scholar
Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004, 17: 16S-20S.
Article
CAS
PubMed
Google Scholar
Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation. 2004, 109: 1536-1542. 10.1161/01.CIR.0000124061.78478.94.
Article
CAS
PubMed
Google Scholar
Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G: Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation. 2004, 110: 3062-3067. 10.1161/01.CIR.0000137970.47771.AF.
Article
CAS
PubMed
Google Scholar
Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000, 355: 253-259.
Article
CAS
Google Scholar
Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004, 22: 2253-2261. 10.1097/00004872-200412000-00003.
Article
CAS
PubMed
Google Scholar
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B: Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens. 2002, 20: 1879-1886. 10.1097/00004872-200209000-00035.
Article
CAS
PubMed
Google Scholar
Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004, 109: 2054-2057. 10.1161/01.CIR.0000127955.36250.65.
Article
CAS
PubMed
Google Scholar
Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM: Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J Hypertens. 2012, 30 (1): 87-96. 10.1097/HJH.0b013e32834dde5f.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E: Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol. 2012, 11: 139-10.1186/1475-2840-11-139.
Article
PubMed Central
CAS
PubMed
Google Scholar
Guo Z, Zhang R, Li J, Xu G: Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats. Cardiovasc Diabetol. 2012, 11: 94-10.1186/1475-2840-11-94.
Article
PubMed Central
CAS
PubMed
Google Scholar
Duan SZ, Usher MG, Mortensen RM: Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008, 102: 283-294. 10.1161/CIRCRESAHA.107.164384.
Article
CAS
PubMed
Google Scholar
Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M: Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology. 2001, 142: 3125-3134. 10.1210/en.142.7.3125.
CAS
PubMed
Google Scholar
Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000, 102: 1834-1839. 10.1161/01.CIR.102.15.1834.
Article
CAS
PubMed
Google Scholar
Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA: Recipes for Creating Animal Models of Diabetic Cardiovascular Disease. Circ Res. 2007, 100: 1415-1427. 10.1161/01.RES.0000266449.37396.1f.
Article
CAS
PubMed
Google Scholar
Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med. 2004, 10: 355-361. 10.1038/nm1025.
Article
CAS
PubMed
Google Scholar
Ji Y, Lui J, Wang Z, Liu N, Gou W: PPARã agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009, 89: 887-902. 10.1038/labinvest.2009.45.
Article
CAS
PubMed
Google Scholar
Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME: Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002, 11: 21-30.
Article
CAS
PubMed
Google Scholar
Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005, 15;4: 6.
Article
Google Scholar
Tiyerili V, Müller CF, Fung S, Panek D, Nickenig G, Becher UM: Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ. J Mol Cell Cardiol. 2012, 53 (2): 268-276. 10.1016/j.yjmcc.2012.05.008.
Article
CAS
PubMed
Google Scholar
Taguchi I, Inoue T, Kikuchi M, Toyoda S, Arikawa T, Abe S, Node K: Pleiotropic effects of ARB on dyslipidemia. Curr Vasc Pharmacol. 2011, 9 (2): 129-135. 10.2174/157016111794519336.
Article
CAS
PubMed
Google Scholar
Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999, 20: 649-688. 10.1210/er.20.5.649.
CAS
PubMed
Google Scholar
Westerink J, Visseren F: Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 2011, 10: 13-10.1186/1475-2840-10-13.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ji Y, Liu J, Wang Z, Lui N: Angiotensin II induces inflammatory response partly via Toll-Like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2009, 23: 265-276. 10.1159/000218173.
Article
CAS
PubMed
Google Scholar
Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002, 287: 2570-2581. 10.1001/jama.287.19.2570.
Article
CAS
PubMed
Google Scholar
Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K: Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care. 2005, 28: 355-359. 10.2337/diacare.28.2.355.
Article
PubMed
Google Scholar
Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F: Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005, 45: 1449-1457. 10.1016/j.jacc.2004.11.067.
Article
CAS
PubMed
Google Scholar
Renard C, Van Obberghen E: Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models?. Diabetes Metab. 2006, 32: 15-29. 10.1016/S1262-3636(07)70243-4.
Article
CAS
PubMed
Google Scholar
Andraws R, Brown DL: Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007, 99: 1006-1012. 10.1016/j.amjcard.2006.10.068.
Article
CAS
PubMed
Google Scholar
Geng DF, Jin DM, Wu W, Xu Y, Wang JF: Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients. Int J Cardiol Int J Cardiol. 2012, 155 (2): 236-242. 10.1016/j.ijcard.2010.10.011.
Article
PubMed
Google Scholar
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004, 363 (9426): 2022-2031. 10.1016/S0140-6736(04)16451-9.
Article
CAS
PubMed
Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003, 9386: 777-781.
Article
Google Scholar
Watanabe M, Inukai K, Sumita T, Ikebukuro K, Ito D, Kurihara S: Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med. 2010, 49 (17): 1843-1847. 10.2169/internalmedicine.49.3189.
Article
CAS
PubMed
Google Scholar
Sakamoto M, Suzuki S, Hayashi T, Iuchi H, Isaka T, Sakamoto N: Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. Cardiovasc Diabetol. 2012, 11: 118-10.1186/1475-2840-11-118.
Article
PubMed Central
CAS
PubMed
Google Scholar
Nishida Y, Takahashi Y, Nakayama T, Asai S: Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovasc Diabetol. 2012, 11: 53-10.1186/1475-2840-11-53.
Article
PubMed Central
CAS
PubMed
Google Scholar